Immuno-Oncology

Toward more predictive preclinical tumor mouse models: conventional tumor models with immunodeficient animals only monitor the effect of a drug on the tumor itself. The approval in 2011 of the first immune-checkpoint inhibitor (Nobel price winner in 2018) has validated the immuno-oncology therapeutic approach against many forms of cancer. The reconstitution of the full functional human immune system in immune-deficient triple KO mice such as NOG/NCG/NSG/BRG provides a unique opportunity to assess the efficacy of new drug candidates acting on both human immune cells such as T cells, myeloid cells and NK cells, and on the tumor itself (bi-specific mAb, ADCC mediation, …) with either Solid (Melanoma, breast, ovarian,…) or Liquid (T-cell lymphoma, B-cell Lymphoma, AML)  tumors.

DATA Driven with more than 

Oncolytic Virus Efficacy in hu-mouse

Colon carcinoma. Treatment with oncolytic virus (intra-tumor vs i.v. injection)

Bi-Specific Ab with ADCC activity

T Cell Immunity – Vaccination

Transient Boost with human Cytokines

TransCure Services CSO’s, Sebastien Tabruynspeaks to LABIOTECH about Immuno-Oncology Research with its Full Human Immune System Mouse Models.

Find out about our Disease Models:

Cancer/Immuno-oncology/PDX  --  Infection-HIV  --  Inflammation - IBD  --  Vaccine - Immunization  --  GvHD   --  Hu-liver  --  Asthma